Objective: The aim of this prospective longitudinal study was to identify static and dynamic O-(2-[ 18 F]fluoroethyl)-L-tyrosine PET ( 18 FET-PET)-derived imaging biomarkers in patients with glioblastoma (GBM).
Glioblastoma (GBM) is a fatal intrinsic brain tumor with median survival times of 11 to 15 months. 1 Current standard of care includes resection in combination with radiotherapy plus concomitant and adjuvant chemotherapy using temozolomide (RCx/TMZ). 2 Evaluation of imaging biomarkers derived from PET and MRI might improve prognostic evaluation, adjustment of treatment strategies, and monitoring of treatment response. [3] [4] [5] So far, PET is mainly used in the setting of differential diagnosis of suspected gliomas, identification of anaplasia, or malignant progression. 6, 7 In addition, it could modify/improve radiation treatment planning in combination with MRI. 8 Retrospective data have indicated that the biological tumor volume (BTV) before radiation therapy as defined by amino acid PET might correlate with poor outcome in patients with GBM: those with smaller BTVs before radiation did significantly better. 9 The current prospective study was conducted to elucidate the prognostic relevance of BTV before radiation plus concomitant TMZ as defined by O-(2-[ 18 F]fluoroethyl)-L-tyrosine PET ( 18 FET-PET). It was planned to include 2 patient cohorts of similar size either undergoing biopsy only or tumor resection. Patients with resectable tumors were considered candidates for microsurgery, whereas patients with eloquent tumor location were candidates for biopsy only. All patients were intended to receive RCx/TMZ according to the European Organization for Research and Treatment of Cancer/National Cancer Institute of Canada (EORTC/NCIC) protocol. 2 Our hypothesis was that BTV before concomitant RCx would be a prognostic/predictive factor independent of the mode of the surgical procedure. Beyond that primary aim of the study, we performed an explorative analysis of static and dynamic PET variables before/after treatment and their possible correlations with outcome.
METHODS Study design. This prospective, longitudinal, multicenter study (www.clinicaltrials.gov NCT01089868) was performed within the context of the German Glioma Network, a noninterventional, consortional, prospective study funded by the German Cancer Aid (Deutsche Krebshilfe, 70-3163-Wi 3) (www.gliomnetzwerk.de). Adult patients were eligible if they had a supratentorial GBM with histology proven by stereotactic biopsy or open tumor resection, no history of surgery, radiotherapy, or chemotherapy, and a Karnofsky performance score (KPS) $70. Exclusion criteria were pregnancy and inability to undergo MRI or 18 FET-PET for any reason. Patients with resectable tumors underwent microsurgical resection (cohort A) and those with unresectable tumors underwent stereotactic biopsy (cohort B). All patients were scheduled to receive RCx/ TMZ according to the EORTC/NCIC protocol 2 and to have 18 FET-PET preoperatively, postoperatively (cohort A only), at 4 to 6 weeks after RCx in analogy to MRI, and after the first 3 cycles of adjuvant TMZ (figure e-1 on the Neurology ® Web site at Neurology.org). MRI and PET were obtained at the same time points with the specification that the postoperative MRI performed in cohort A was scheduled within the first 72 hours after surgery. The study was designed to elucidate in particular the prognostic role of BTV. We planned to include at least 72 patients equally distributed in both cohorts. Given an accrual period of 36 months and a follow-up time of 3 years, this sample size would allow identifying biomarkers exhibiting a hazard ratio of 2 or higher with a statistical power of 80%. In addition, the study explored the prognostic relevance of dynamic 18 FET-PET-derived biomarkers. Power calculation, however, did not refer to these analyses.
Inclusion period was from February 2007 until January 2010; date of last follow-up evaluation was February 28, 2014. Primary endpoint was overall survival (OS), and secondary endpoint was progression-free survival (PFS).
Standard protocol approvals, registrations, and patient consents. All patients gave written informed consent, and the prospective study protocol was approved by the institutional review board of the Ludwig-Maximilians University, Munich, Germany (AZ 216/04) as well as the institutional review board of participating sites. MRI protocol. MRI was performed at the above-mentioned time points on 1.5T or 3.0T scanners (Philips Intera 3T, Andover, MA, and Signa HDxt, GE Healthcare, Milwaukee, WI). The standardized sequence protocol comprised an axial diffusion-weighted, an axial T2-weighted, an axial fluidattenuated inversion recovery (FLAIR) sequence, and isovoxel (3-dimensional) T1-weighted gradient-echo sequences. Two experienced neuroradiologists (J.L., H.J), blinded to the results of 18 FET-PET investigations, evaluated the MRI scans including volumetric analyses of each tumor under investigation. For a detailed description of the MRI protocol, see appendix e-1. 18 FET-PET protocol. Fifty-minute dynamic emission recording was initiated after injection of approximately 180 MBq 18 FET with either a standalone PET (EACT EXACT HR1) or a PET/CT (Biograph) scanner (Siemens Medical Systems, Erlangen, Germany) according to a standardized acquisition protocol. Semiquantitative PET data assessment included the maximal standardized uptake value (SUV) of the tumor corrected for the mean background activity in the healthy contralateral hemisphere reflecting the lesion to brain ratio (LBR max ) and the estimated BTV defined by semiautomatic threshold-based calculation of a volume of interest (LBR $1.8). Because previous studies have reported 1.6 as optimal cutoff for untreated glioma 10 and a cutoff value of 2.0 for pretreated glioma, 11 we considered a threshold of 1.8 to be most appropriate for longitudinal assessment of GBM before and after therapy.
Evaluation of dynamic PET recordings was assessed according to our standardized procedure. 6 Resulting time-activity curves (TACs) were classified into 2 groups: (1) decreasing TAC with SUV showing an early peak within the first 20 minutes followed by a constant descent thereafter, or (2) increasing TAC with SUV constantly ascending or followed by a plateau (for further details, see appendix e-1).
Histology and MGMT analysis. Histologic diagnosis was made centrally (H.K.) according to the World Health Organization classification. 12 MGMT (O-6-methylguanine-DNA methyltransferase) analysis was performed using methylationspecific PCR. 13 Statistical analysis. Reference point of the study was the date of surgery. Endpoints were death and date of tumor progression. All patient files were reviewed centrally (J.C.T. and M.W.). Statistical analysis was performed using the SPSS 17.0 software package (SPSS, Inc., Chicago, IL). PFS and OS were analyzed using the Kaplan-Meier method. Comparison of survival curves was done with the 2-sided log-rank test. Categorical variables were analyzed with the x 2 test and continuously scaled variables with the Wilcoxon test. Wilcoxon test for related samples was used to analyze changes of static/dynamic FET measures over time. Correlation between continuously scaled variables was described with Pearson correlation coefficient. Potential prognostic factors were identified using proportional hazards models. Parameters that were significant in univariate analyses were included in multivariate models. The optimized model contained only variables that were significantly associated with the endpoint of interest after adjustment for the effects of other variables included in the model. Receiver operating characteristic (ROC) curve analysis identified cutoff values of continuously scaled imaging biomarkers of interest.
RESULTS Study population. Ninety-two patients were screened for study entry. Seventy-nine patients fulfilled the inclusion criteria (figure e-2): 42 were assigned to cohort A (resection) and 37 to cohort B (biopsy). Age, initial KPS, sex distribution, the frequency of MGMT promoter methylation, and the applied treatment did not differ in both cohorts. Patient characteristics are summarized in table e-1.
On the date of last follow-up, 70 patients had died (37 in cohort A, 33 in cohort B). Two deaths were not GBM-associated and were handled as censored events at the time of their last follow-up. Two patients were lost to follow-up. Five patients are still alive (median follow-up: 48.6 months). Seventy-six patients experienced tumor progression (40 patients in cohort A and 36 patients in cohort B). Sixty-four patients underwent a complete course of RCx, 12 patients did not undergo RCx for various reasons, and in 3 patients, RCx was disrupted because of progressive clinical deterioration. Thirty-one patients received 3 cycles of TMZ and thus completed the PET study protocol as planned. The frequency of incomplete or not begun RCx course was slightly higher in the biopsy group (14% vs 24%, p 5 0.5). Overall, median PFS was 7.6 months (95% confidence interval: 4.2-11.0) and median OS was 13.5 months (95% confidence interval: 10.9-16.7). PFS and OS did not differ significantly between the 2 cohorts. In those undergoing a complete course of RCx, however, OS was longer after surgery than after biopsy (median OS: 16.7 vs 13.4, p 5 0.02).
Median initial BTV was 23.8 cm 3 , and median initial LBR max was 3.6; nearly identical values were seen in both cohorts (table 1 and table e-2) . Initial TAC was decreasing in 59 of 74 tumors and increasing in 15 of 74 tumors. In 5 tumors, TAC data were not available.
MRI-based volumetric estimations of the gadolinium enhanced (Gd1) volume including necrotic/cystic areas and the Gd1 volume alone were 35.7 cm 3 (median) and 13.5 cm 3 , respectively, while T2/ FLAIR volume accounted for 75.0 cm 3 . The volume distribution was as follows: T2/FLAIR . Gd1 volume including necrotic/cystic parts . BTV . Gd1 volume alone.
BTV before RCx. Initial BTV gained prognostic relevance for OS in the biopsy group (p 5 0.002): those with smaller BTV did better. In the surgery group, BTV was associated with outcome only after surgery (OS: p 5 0.002; PFS: p 5 0.02). To determine the potential significance of BTV and SUV max /background (BG) before RCx (BTV preRCx and SUV max / BG preRCx ; table 1), postsurgical values of cohort A and the initial values of cohort B were analyzed together. BTV before radiotherapy (referred to as BTV preRCx in the following) showed a strong association with survival. According to ROC analyses, the cutpoint of BTV preRCx was estimated to be 9.5 cm 3 (sensitivity 64%, specificity 70%). Median OS (PFS) for those with a BTV preRCx below 9.5 cm 3 was 17.5 (8.8) months, and 10.7 (3.9) months for those with a BTV preRCx above 9.5 (p 5 0.002 and p 5 0.08) ( figure 1, A and B) . The prognostic impact of BTV preRCx was independent of the applied mode of surgery and remained statistically significant in each of the cohorts. The prognostic/predictive impact of BTV preRCx pertained also in the subgroup of 64 patients who completed the course of RCx (OS: p 5 0.007; PFS: p 5 0.13). Median BTV preRCx was significantly smaller in the resection group than in the biopsy group (0.8 and 20.1, p , 0.0001); however, an overlapping distribution of the BTV preRCx between the cohorts exists.
In those with a BTV preRCx below 9.5 cm 3 , the median Gd1 volume and Gd1 volume including necrotic areas was 0.61 cm 3 (range 0-29.6 cm 3 ) and 1.81 cm 3 (range 0.0-58.9 cm 3 ), respectively. The corresponding values for those with a BTV preRCx above 9.5 cm 3 were 12.2 cm 3 (range 0.4-69.5 cm 3 ) and 24.3 cm 3 (range 0.46-95.9 cm 3 ), respectively. A similar distribution was observed in the biopsy group compared with the resection group.
In MRI before RCx, a smaller Gd1 volume (without necrotic or cystic parts) was also associated with prolonged OS (p 5 0.006); Gd1 volume plus necrotic tumor parts and T2/FLAIR estimated volume did not gain prognostic impact. See figure 2 for patient examples of BTV compared with Gd1 volume.
LBR max and TAC before RCx. Initial LBR max values showed no association with PFS or OS in cohort A or B either considered separately or pooled. However, those with lower LBR max (LBR max-preRCx ) values experienced longer PFS and OS. According to ROC analysis, the cutpoint for LBR max-preRCx was 2.9 (sensitivity 68%, specificity 73%; p , 0.0001, hazard ratio [HR] 2.9, for OS; and p 5 0.01, HR 2.0, for PFS) ( figure 1, C and D) .
The initial TAC pattern was associated with prognosis: patients exhibiting increasing TAC experienced longer OS (29.7 vs 12.5 months; p 5 0.02, HR 2.1) ( figure 1E ) and longer PFS (11.9 vs 5.8 months; p 5 0.05, HR 1.8) ( figure 1F ). LBR max , BTV, and TAC changed from decreasing to increasing in 16 patients, remained increasing in 6 patients, and changed from increasing to decreasing in 5 patients. A change from decreasing to increasing TAC was associated with longer PFS compared with patients in whom TAC pattern remained decreasing (6.5 vs 3.4 months; p 5 0.017). Patients with a persistently increasing TACs had a longer PFS than those in whom the pattern changed from increasing to decreasing (16.7 vs 10.6 months, p 5 0.4; figure 3 ).
Multivariate analyses. A methylated MGMT promoter status, higher initial KPS, young age, increasing initial TAC, smaller BTV preRCx and LBR max-preRCx values, Abbreviations: BTV 5 biological tumor volume; FLAIR 5 fluid-attenuated inversion recovery; Gd1 5 gadolinium enhanced; LBR max 5 maximal lesion to brain ratio; RCx 5 radiochemotherapy; TAC 5 time-activity curve; TMZ 5 temozolomide. The 2 patients lost to follow-up were not considered in the statistical analyses. BTV was determined by 18 and smaller Gd1 volume were favorable prognostic/ predictive covariates for OS in one-variable models. For PFS, it was a methylated MGMT promoter status, higher initial KPS, increasing TAC postRCx , lower BTV preRCx , and Gd1 volume. Multivariately, small BTV preRCx , increasing initial TAC, and MGMT promoter methylation were associated with both longer PFS and OS. In addition, higher KPS values (A, B) , LBR max-preRCx (C, D), and initial TAC (E, F) with overall survival and progression-free survival BTV preRCx 5 biological tumor volume before radiochemotherapy; LBR max-preRCx 5 maximal lesion to brain ratio before radiochemotherapy; TAC 5 time-activity curve.
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were associated with longer OS. Results of univariate and multivariate models are detailed in table 2. Nearly identical results were obtained for those undergoing a complete course of RCx (data not given, available on request).
DISCUSSION
In the current prospective study, the BTV preRCx proved to be a powerful 18 FET-PETderived imaging biomarker. In patients with smaller BTV preRCx , either after biopsy or tumor resection, OS and PFS were significantly better, which remained true after adjustment for the effects of treatment, MGMT promoter methylation, and other patientand tumor-related factors. This finding confirms our initial hypothesis. In the biopsy group, the initial BTV (equivalent to the BTV preRCx in this group) gained prognostic relevance, whereas in the resection group, this was detectable only for the postresection BTV (which is BTV preRCx in this group). Because minimal BTV preRCx is strongly linked to OS, maximal surgical reduction of the BTV seems to be essential in resectable tumors. This might explain why the initial BTV in the surgery group did not gain any impact on outcome in contrast to the finding in the biopsy group. Of note, removal of only necrotic parts of the tumor volume seems not to alter the prognosis because MRI-based Gd1 volume was also significantly associated with OS while Gd1 volume including necrotic/cystic area and T2/FLAIR volume was not. This is in line with data from a previous multicenter study with MRI as the only imaging modality. 14 The optimal threshold for favorable/unfavorable BTV after biopsy/surgery still needs elucidation and could not be precisely resolved by the design of this Abbreviations: BTV 5 biological tumor volume; CI 5 confidence interval; Gd1 5 gadolinium enhanced; KPS 5 Karnofsky performance score; LBR max 5 maximal lesion to brain ratio; MGMT 5 O-6-methylguanine-DNA methyltransferase; OS 5 overall survival; PFS 5 progression-free survival; postRCx 5 after radiochemotherapy; preRCx 5 before radiochemotherapy; TAC 5 time-activity curve. BTV was determined by 18 and other studies. 9 However, a postresection GD1 volume of approximately 0 cm 3 in the surgery group can harbor a BTV preRCx of up to 9.5 cm 3 . This might explain why survival in both cohorts was rather similar even though BTV preRCx was lower in the surgery group. A moderate survival benefit was detected after surgery only for those patients completing RCx. This implies that BTV-based prognostic evaluation will refine indications for open tumor resection and biopsy in patients with GBM: in lesions that are not amenable for a safe and significant surgical reduction of the biologically relevant active tumor volume (which will not be achieved by removal of necrotic tissue only), the role of surgery might be questionable whereas patients with large BTVs and surgically accessible tumors might be good candidates for tumor resection.
The association of the LBR max-preRCx and outcome, although positively correlated with the respective BTV, was more heterogeneous; its impact was clearly dominated by the BTV preRCx in multivariate models.
The optimal time point for PET-guided assessment of treatment response after RCx of patients with GBM remains unknown. We demonstrate that both BTV and LBR max significantly decreased 6 weeks after RCx, but with no prognostic threshold for these static measures. Unspecific 18 FET uptake in treatment-induced reactive gliosis might have confounded the discrimination between responders and nonresponders in the current study. 15 Recently published studies showed conflicting results: a significant influence was found 6 to 8 weeks after RCx; however, this was not confirmed after a longer observation time. 16, 17 Whether a PET scan 7 to 10 days after RCx is more reliable for the evaluation of treatment response has yet to be elucidated. 9 Nevertheless, short time evaluation could interact with occurrence of pseudoprogression. Because imaging was conducted after 6 to 8 weeks in our study, only 2 patients showed pseudoprogression in MRI. Of note, there was no correlating increase in BTV in those patients. This small number is in line with a recent publication examining the incidence of pseudoprogression. 18 Thus, future prospective studies should resolve uncertainties concerning appropriate time points for treatment response assessment by static 18 FET-PET analysis.
We have previously demonstrated the prognostic value of 18 FET kinetics in recurrent high-grade glioma. 19 Based on the present study, analysis of TACs and their changes during the disease course offers an additional imaging biomarker for early prognostic evaluation and assessment of treatment response. Initial TAC and TAC changes after RCx had prognostic influence on outcome. These results seem to contrast findings of a recent study in which no influence was detected for several kinetic measures. 17 Notably, in the latter study comprising a small study population, TACs were evaluated in differently defined ROIs: pretherapeutic TACs were assessed within the tumor ROI corresponding to the target volume of radiotherapy, which was subsequently transferred to the coregistered slices of the follow-up PET for the analysis of posttherapeutic TACs. Therefore, the method of dynamic analysis, namely, the ROI definition, seems to be essential for the assessment of the prognostic value. Furthermore, it remains subject to further investigations to elucidate whether tumors exhibiting increasing TACs differ in biology and/or vascularity from those with a decreasing pattern. FET uptake is influenced by the expression of amino acid transporters as well as tumor perfusion [20] [21] [22] ; however, the underlying mechanisms concerning the slope of the TAC remain to be explored.
Our study has limitations. First, we did not apply RANO (Response Assessment in Neuro-Oncology) criteria because the study started before their publication. 23, 24 Second, evaluation of TACs was based on a relatively small sample size and deserves further evaluation.
Altogether, 18 FET-PET-derived imaging biomarkers before and after concomitant RCx in GBM are powerful tools to obtain prognostic information for outcome in newly diagnosed GBM. BTV as delineated by 18 FET-PET before RCx/TMZ correlates with PFS and OS. Tumor uptake kinetic of 18 FET is associated with PFS. These findings might help to individualize therapy and response evaluation in forthcoming clinical investigations.
